Inhibikase Therapeutics Announces Appointment of Elizabeth O’Farrell to its Board of Directors ATLANTA and BOSTON, April 09, 2019 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc., a pharmaceutical company developing protein kinase inhibitors for the treatment of neurological infections and...

Inhibikase Therapeutics Expands its Scientific Advisory Board with the Appointment of Leading Experts in Parkinson’s Disease ATLANTA and BOSTON, March 19, 2019 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc., a pharmaceutical company developing protein kinase inhibitors for the treatment of neurological infections and...

Inhibikase Therapeutics Appoints Leading Experts in Parkinson’s Disease to its Scientific Advisory Board ATLANTA and BOSTON, March 05, 2019 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc., a pharmaceutical company developing protein kinase inhibitors for the treatment of neurological infections and...

Inhibikase Therapeutics Files Two Investigational New Drug Applications for IkT-148009, a Disease-Modifying Therapy for Parkinson’s Disease ATLANTA and BOSTON, Feb. 26, 2019 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc., a pharmaceutical company developing protein kinase inhibitors for treatment of neurological infections and...